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ABSTRACT: The term apoptosis, also known as programmed cell death (PCD), was coined by developmental biologists a num-
ber of years ago to describe a form of cell death characterized by several unique morphological and biochemical features.
Genetic studies of the round worm Caeneorhabditis elegans, a simple multicellular organism, first revealed apoptosis to be an inte-
gral part of the developmental program. Subsequently, the importance of apoptosis in higher organisms was demonstrated in
several eukaryotic systems. In mammals, apoptosis is widespread during embryogenesis and in adult tissues. It is required for
normal tissue homeostasis and for clonal selection in the immune system. In both developing and adult organisms, apopto-
sis plays a central role in reinforcing appropriate cellular patterns and in regulating cell number by eliminating cells that are
harmful or no longer needed. It is becoming increasingly clear that disruption in the apoptosis pathway can contribute to the
development of a number of developmental, inflammatory, degenerative, and neoplastic diseases. The effector arm of the
apoptotic program includes members of the Bcl-2 gene family that function as either death agonists or death antagonists.
These proteins participate in an elaborate genetically controlled biochemical pathway that functions to maintain tissue and
organ homeostasis and serve as a critical defense mechanism to guard against malignant transformation. Cancer is the result
of a series of genetic lesions that include activation of oncogenes and inactivation or loss of tumor suppressor genes. Several
groups of investigators have observed that deregulated expression of oncogenes can subvert apoptotic pathways, resulting in
prolonged cell survival. In pathological settings such as cancer, members of the Bcl-2 gene family are able to synergize with
oncogenes and tumor suppressor genes to transform cells. In this review, we describe the process of apoptosis in mammalian
cells and define the role and biochemical pathways through which the Bcl-2 gene family induce and/or protect cells from apop-
tosis. Last, we will discuss the evidence which suggests that alterations in this pathway may play a central role in tumorigen-
esis by allowing genetically damaged cells normally destined for elimination to persist, predisposing them to additional muta-
tions and driving them to malignancy.
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The Apoptotic Program
Apoptosis is a tightly regulated process designed to
remove superfluous, damaged, or senescent cells
from an organ or tissue (Glucksmann, 1951; Kerr et al.,
1972; Wyllie, 1980; Arends and Wyllie, 1991; Collins,
1991; Goldstein et al., 1991; Williams, 1991; Koli and
Keski, 1992. Sen, 1993). Induction of this endogenous
"suicide" program is triggered by a variety of environ-
mental signals such as DNA or protein damage, toxins,
growth or nutrient factor withdrawal, and ligand binding
(Ijiri, 1989; Barry et al., 1990; Muschel et al., 1991; Bazar
and Deeg, 1992; Hardin et al., 1992; Hickman, 1992;
Potten et al., 1992; Raff, 1992; Waters, 1992; Manchester et
al., 1993; Nagata, 1994, 1997; Venkatatachalam et al.,
1993). This process (Table 1), which occurs over several
hours or days, is characterized by cytoskeletal disruption,
cell shrinkage, condensation and margination of chro-
matin, activation of endonucleases, and cellular frag-
mentation into small membrane-bound structures
termed apoptotic bodies, that are phagocytosed by
macrophages or neighboring cells (Barinaga, 1994). The
DNA degradation that occurs is a two-step process that
involves separate pools of endonucleases (Pandey et al.,
1994). The first step is initiated by endonuclease activity
at interloop sites in chromatin and leads to DNA frag-
ments in the 50- to 300-kilobase range. The second stage
of fragmentation is catalyzed by calcium/magnesium-
dependent endonucleases. It results in internucleosomal
DNA cleavage and production of multimers of 180-200
base pairs that can be visualized as a "ladder" on agarose
gels (Walker and Sikorska, 1994; Pandey et al., 1997). All
apoptotic cells undergo DNA fragmentation; however,
not every cell type undergoing apoptosis exhibits inter-
nucleosomal DNA cleavage. The first pool of endonucle-
ase activity is sufficient for cell death (Walker et al., 1994).
DNA fragmentation can be reliably detected at the
single-cell and tissue level by means of the terminal
deoxynucleotidyl transferase (TdT)-mediated dUTP-biotin
nick end-labeling technique, also known as the TUNEL
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TABLE 1
Comparisons between Apoptosis and Necrosis
Necrosis vs. Apoptosis
Morphological Changes
Loss of membrane integrity Membrane blebbing without loss of membrane
integrity
Random fragmentation of chromatin Aggregation and margination of chromatin
Cellular swelling Cellular shrinkage
Cell lysis Formation of apoptotic bodies
Swelling and disintegration of organelles Persistence of apoptotic bodies
Biochemical Changes
Loss of ion homeostasis Genetically controlled activation of enzymes
Passive process (no energy requirement) ATP-dependent process
Random digestion of DNA Generation of non-random oligonucleosomes of
(DNA smear on agarose gel) DNA (ladder pattern on agarose gel)
Late post-lytic DNA fragmentation Early pre-lytic DNA fragmentation
Physiological Significance
Death of large contiguous groups of cells Death of individual or small groups of cells
or organ segments
Evoked by pathological stimuli Evoked by physiological stimuli
Phagocytosis by macrophages Phagocytosis by macrophages or neighboring cells
Acute inflammation No inflammation
assay (Gavrieli et al., 1992). As an indicator of cell death, it
detects 3'-OH DNA ends generated by DNA fragmenta-
tion that are known to occur early in cells destined to die
by apoptosis. The technique is useful for identifying cells
in the early stages of apoptosis by labeling intact apop-
totic nuclei and apoptotic bodies with large DNA frag-
ment breaks as well as single-stranded breaks. The tech-
nique involves a template-independent addition of
deoxyuridine triphosphates to the 3'-OH ends of double-
or single-stranded DNA with either blunt, recessed, or
overhanging ends that is catalyzed by the enzyme TdT.
Depending on the chromogen/substrate used to detect
the labeled 3 -hydroxyl ends, one can readily identify
strand breaks in nuclei and apoptotic bodies in either cell
suspensions or tissue sections. This approach has been
shown in most instances to correlate with other morpho-
logical and biochemical features of apoptosis. However, a
word of caution should be noted. While DNA fragmenta-
tion is certainly an indicator of apoptosis, it is also a fea-
ture of cell replication. During cell replication, DNA sin-
gle-strand breaks are required to uncoil the double helix
for binding of enzymes necessary for replication (Bohr et
al., 1986). Thus, the identification of apoptotic cells by the
TUNEL assay in the absence of other cytopathic or bio-
chemical changes indicative of apoptosis should be inter-
preted with guarded confidence. The potential for erro-
neous interpretation of the
TUNEL assay data was recent-
ly demonstrated by Wrone-
Smith et al. (I1997). These inves-
tigators reported that despite
the presence of TUNEL-posi-
tive keratinocytes derived from
psoriatic plaques, psoriatic
keratinocytes were observed to
be resistant to the induction of
apoptosis as measured by
electrophoretic detection of
DNA fragmentation (DNA lad-
der). This demonstrates that
one should not rely on a single
assay for assessing apoptosis.
A loss of mitochondrial
function is also an important
feature of apoptosis, and sev-
eral lines of evidence suggest
that the integrity of mitochon-
drial membranes and changes
in cytochrome c efflux have a
profound influence on the
subsequent biochemical
events that lead to cell death
(Adachi et al., 1997; Kluck et al.,
1997; Yang et al., 1997). This
chronic, genetically regulated, and predictable form of
cell death typically involves single cells or small groups
of cells and does not provoke an inflammatory response.
This is in distinct contrast to cell necrosis, which results
from acute toxic injury. This form of cell death usually
involves large contiguous groups of cells and major seg-
ments of an organ or tissue. Typically, cellular necrosis is
associated with rapid cellular swelling due to the inabil-
ity of cells to maintain ion homeostasis. As a conse-
quence, the membrane integrity of organelles is severely
compromised early in the process, with random DNA
degradation occurring late in the cell's demise (Kerr et al.,
1972). The induction of an acute inflammatory response
invariably accompanies this form of cell death.
The process of apoptosis has been described as con-
sisting of three distinct phases: initiation, effector, and
degradation (Kroemer, 1997). The initiation phase is medi-
ated by a variety of diverse stimuli that act to trigger the
response. These triggers include, among others: radiation-
induced DNA and protein damage, reactive oxygen mole-
cules, or proteases; withdrawal of essential nutrients,
growth factors, or hormones during critical stages in cell
growth and maturation; and binding of ligands such as
Fas, tumor necrosis factor-ox, interferon gamma, inter-
leukin-1, or transforming growth factor-D to their corre-
sponding cell membrane receptors. The signal transduc-
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tion pathways that regulate apoptosis and initiate the
downstream effector and degradation phases are common
to most apoptotic processes. It is known that the apoptot-
ic regulatory machinery involves several groups of mole-
cules, including the Bcl-2 family of proteins (to be dis-
cussed in greater detail below), and a number of enzymes
(see Mundel et al., 1996, for review), including: granzymes
or serine proteases (Greenberg and Litchfield, 1995; Shi et
a!., 1992), ceramides (Obeid et al., 1993; Zhang et al., 1996),
tissue transglutaminases (Fesus et al., 1987, 1989;
Piacentini et al., 1991), lamin proteinases (Lazebnik et al.,
1995), phosphatases (Morana and Eastman, 1995),
inducible nitric oxide synthase (Ankarcrona et al., 1994;
Kitajima et al., 1994; Blanco et al., 1995), the caspases or
interleukin- I 3-converting enzyme (ICE) family of cysteine
proteases (Barinaga, 1994; Duan et al., 1996; Henkart,
1996), poly(ADP-ribose) polymerases (PARP) (Henkart,
1996; Ray et al., 1992; Rice et al., 1992), and nucleases
(Arends et al., 1990; Hughes and Cidlowski, 1994).
Knowledge of the mechanisms underlying the apoptotic
process continues to expand at an exponential rate, and
key signal transduction pathways that regulate apoptosis
and control the function of these family members are just
now being identified. Several excellent reviews have been
published in the last several years on the structure, func-
tion, and mechanism of action of the apoptotic program
(Arends and Wyllie, 1991; Goldstein et al., 1991; Sen, 1993;
Korsmeyer, 1995; Manning and Patierno, 1996; Mundel et
al., 1996; Nagata, 1997). Thus, details regarding these
aspects of apoptosis will not be discussed here. For the
remainder of this review, we will focus on a key component
of the effector arm of the apoptotic program, the Bcl-2
gene family of proteins, and discuss how they contribute
to the pathogenesis of disease, specifically, their role in
the development of cancer.
The Bcl-2 Gene Family of Proteins
The centerpiece of the apoptotic program and the major
effector arm of the cell death program is the Bcl-2 family
of related proteins (Table 2) (Nufiez and Clarke, 1994;
Reed, 1994; Korsmeyer, 1995; Kroemer, 1997). The proto-
type member of this family is Bcl-2, an acronym for B-cell
lymphoma/leukemia-2 gene, that was first discovered at
the breakpoint of the t(14;18) in a follicular non-
Hodgkin's B-cell lymphoma (Tsujimoto et al., 1985). In this
translocation, the Bcl-2 gene is moved from its normal
chromosomal location at 18q21 into proximity with pow-
erful enhance elements in the immunoglobulin heavy-
chain (IgH) locus at 14q32. This results in deregulation of
the translocated Bcl-2 gene and overproduction of Bcl-2
mRNAs and their encoded proteins (Bakhshi et al., 1985).
The Bcl-2 gene family consists of two opposing groups of



















Brag- 1, Mcl- 1, and A- 1) and death agonists (Bax, Bak, Bcl-
xS, Bad, Bid, Bik, and Hrk) (Kroemer, 1997). They differ in
their tissue- and activation-dependent patterns as well as
in their structure (Hockenbery et al., 1991; LeBrun et al.,
1993; Krajewski et al., 1994a,b). The proteins encoded by
the Bcl-2 family localize to the outer mitochondrial mem-
brane, the nuclear membrane, and the endoplasmic retic-
ulum (Korsmeyer, 1995; Kroemer, 1997). The protein prod-
ucts of the gene family share two highly conserved
domains, BHI and BH2 (Bcl homologue 1 and 2), that
regulate heterodimerization between the death antago-
nists such as Bcl-2 and Bcl-XL and death agonists like
Bax. Cell death is induced by this gene family through
competing dimerization (Oltvai and Korsmeyer, 1994). If,
for example, the level of Bcl-2, which protects cells from
undergoing apoptosis, is higher than the level of the
death inducer Bax, Bcl-2 homodimers prevail and cells
are protected. If, on the other hand, Bax is in excess, the
opposite effect occurs and cells become susceptible to
apoptosis. Thus, it is the ratio (relative level of expres-
sion) of proteins that either protect or induce cell death
which determines the ultimate fate of a cell (Korsmeyer,
1995). Indeed, there is now substantial evidence that
these domains play a critical role in how a cell responds
to death-inducing and death-protecting signals (Kroemer,
1997). The BH3 domain of death agonists such as Bax and
Bak is required for these proteins to heterodimerize with
Bcl-2 and Bcl-xL to promote apoptosis (Zha et al., 1996;
Kroemer, 1997). Overexpression of those proteins con-
taining only the BH3 domain is sufficient for interacting
with and inhibiting the function of Bcl-2-like survival pro-
teins. Thus, this class of proteins thus functions as dom-
inant negative inhibitors of cell death.
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Role of the Bcl-2 Family of Proteins and Caspases in








Figure. The illustration depicts the interaction of the Bcl-2 gene family
members with key Cytosolic Aspartate-Specific cysteine Proteases
(Caspases) (Mignotte and Vayssiere, 1 998). Bcl-2 is located at the
contact points between the inner and outer mitochondrial membranes,
and along the nuclear membrane and endoplasmic reticulum. BcI-XL is
present in both soluble and membrane-bound forms while Bax is locat-
ed predominantly in the cytosol. The current speculation is that Bcl-
2/Bcl-XL and perhaps other members of the Bcl-2 family inhibit apop-
tosis by maintaining the Apaf-1/pro-Caspase 3 (CPP 32) complex
bound tightly to membranes. When Bax, Bid, or Bad heterodimerizes
with Bcl-2/Bcl-xL, the complex dissociates, resulting in activation of
pro-Caspase 3 and cell death.
Bcl-2 is an Antagonist of Cell Death
Bcl-2 functions to confer a survival advantage to a variety
of cell types by inhibiting apoptosis. The death-inhibito-
ry effect of Bcl-2 was first reported in studies of an IL-3-
dependent B-lymphocyte line (Vaux et al, 1988). Growth
and survival of these cells are strictly dependent on the
presence of IL-3 in the culture media. When Bcl-2 was
overexpressed in these cells, they were able to survive in
the absence of IL-3. Also, B-lymphocytes immortalized
with the Epstein-Barr virus constitutively overexpress
Bcl-2 and exhibit prolonged cell survival in culture
(Henderson eL cil., 1991, Oren, 1992). The c-myc onco-
gene, when introduced into rat fibroblasts, induces cell
proliferation in serum-supplemented culture media
With serum deprivation, apoptosis ensues but can be
blocked by Bcl-2 (Bissonnette et al., 1992; Evan et al.,
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1992; Wagner et cil, 1993). Overexpression of Bcl-2 has
been shown to inhibit apoptosis induced by a number of
agents, including calcium ionophores, ethanol, irradia-
tion, corticosteroids, cyclic AMP, and heat-shock (Barry et
al, 1990; Baxter and Lavin, 1992, Ray et al., 1992).
Interestingly, the introduction of Bcl-2 into a variety of
epithelial and mesenchymal cells inhibits cell death but
does not enhance cell proliferation (Oren, 1992, Manning
and Patierno, 1996). Further insights into the function of
Bcl-2 during apoptosis and the consequences of its inap-
propriate expression have been revealed in both gain-of-
function and loss-of-function experiments (McDonnell et
al, 1989; Veis et al., 1993). Transgenic mice bearing a Bcl-
2-immunoglobulin minigene initially showed a polyclo-
nal follicular expansion of B-cells in GO/GI of the cell
cycle. Cells accumulated because they lived longer rather
than due to increased cell proliferation. Eventually, the
expanded B-cells progressed to high-grade lymphomas
due to the occurrence of a translocation involving the c-
myc oncogene in a large number of these tumors
(McDonnell et al, 1989; McDonnell and Korsmeyer, 1991;
Korsmeyer, 1995). Thus, the proliferative advantage
afforded by c-myc overexpression was complemented by
and synergized with the increased survival caused by
overexpression of Bcl-2. In the mouse embryo, Bcl-2 is
expressed much more widely than in adult tissues. This
raised the question by Korsmeyer and colleagues
whether this key repressor of cell death would be
required for the successful development of multiple lin-
eages (Korsmeyer, 1995). Mice with a targeted disruption
in Bcl-2 exhibited normal development until the first
week after birth, suggesting the function of redundant
genes that control apoptosis during this phase and that
can overcome the lack of Bcl-2. Hematopoiesis appeared
normal, indicating that Bcl-2 was not required for the
development of these lineages Most organs in these
mice develop normally However, one week after birth,
homozygous mutants exhibited growth retardation, with
small ears and immature facial features. The mice died at
an early age and exhibited diffuse apoptosis of their kid-
neys which progressed to severe polycystic kidney dis-
ease (Veis et cil, 1993).
Mechanism of Action of the Bcl-2 Protein
The mechanism by which Bcl-2 inhibits apoptosis is still
uncertain and thus remains the subject of intensive
investigation. Bcl-2 has been localized to areas of con-
tact between the outer and the inner mitochondrial
membranes, suggesting that Bcl-2 may protect cells from
apoptosis by altering mitochondrial function. There is
evidence that Bcl-2 might act to prevent calcium influx
into mitochondria induced by growth factor withdrawal
and prevent cytochrome c outflow from the intermem-
brane space (Adachi et al., 1997). The observation that
suppression of DNA fragmentation by Bcl-2 overexpres-
sion is associated with decreased levels of cytosolic cal-
cium and increased levels of mitochondrial calcium sug-
gests that Bcl-2 may be involved in the regulation of
intracellular calcium distribution. This is further support-
ed by the observation that calcium-ionophore-induced
apoptosis is substantially reduced in cells overexpress-
ing Bcl-2. The localization of Bcl-2 to the nuclear mem-
brane and in mitotic nuclei suggests that it may protect
DNA from damage by endonucleases.
Recently, a homologue of Bcl-2, called Bcl-x, has
been cloned and characterized. As a result of alternative
splicing, two mRNA species, designated Bcl-xL and Bcl-
XS' were identified in humans (Boise et al., 1993). The for-
mer, like Bcl-2, inhibits apoptosis. The latter is a domi-
nant negative repressor of Bcl-2 and enhances apoptotic
signals in cells which express Bcl-2. The structure of Bcl-
XLiS strikingly similar to the pore-forming domain of
diphtheria toxin. This suggests that this Bcl-2-related
protein and perhaps Bcl-2 itself may function as ion
channels (Minn et al., 1997; Schendel et al., 1997). The
mitochondrial permeability transition (depolarization of
the transmembrane potential) can cause the outflow of
mitochondrial proteins (e.g., apoptosis-inducing factor,
cytochrome c) into the cytosol and activate specific
apoptogenic proteases such as caspase-3 (Kroemer,
1997). The activation of this caspase is dependent on the
presence of cytochrome c in the cytosol and results in
cleavage of PARP and subsequent DNA fragmentation
(Yang et al., 1997). Therefore, both Bcl-2 and Bcl-xL may
prevent apoptosis by inhibiting cytochrome c transloca-
tion and thus prevent caspase activation and the subse-
quent downstream events in the apoptotic process
(Kluck et al., 1997).
Bcl-2 may also function as an anti-oxidant. Bcl-2 has
been reported to block apoptosis in cells exposed to y-
irradiation which cause damage due to the generation of
reactive oxygen species (Hockenbery et al., 1993; Polyak et
al., 1997). Moreover, H202 and dexamethasone-induced
apoptosis can be overcome by Bcl-2. Hockenbery et al.
(1993) have noted that the death-suppressive effects of
anti-oxidants such as N-acetyl-L-cysteine and glutathione
peroxidase were mediated through inhibition of lipid per-
oxidation. It was proposed that Bcl-2 could act as an anti-
oxidant by a similar mechanism. However, since Bcl-2
expression can also inhibit apoptosis under aerobic con-
ditions, it may be that production of reactive oxygen mol-
ecules is a consequence rather than a cause of apoptosis.
Bcl-2 and the Development of Cancer
There is now compelling evidence that aberrant expres-
sion of one or more members of the Bcl-2 gene family
TABLE 3
Apoptosis-associated Diseases*































Toxin (Alcohol)-induced liver disease
'Adapted from Thompson (1995).
can contribute to the development of a variety of dis-
eases (see review by Thompson, 1995). Table 3 is a list of
developmental, degenerative, inflammatory/immunolog-
ical, and neoplastic diseases associated with either pro-
longed cell survival or premature or excessive cell death.
The evidence implicating Bcl-2 family members in the
development of cancer comes from several lines of study.
Tumor cells from a wide variety of human cancers have
been shown to exhibit increased survival and resistance
to apoptosis (Collins, 1991; Williams, 1991; Oren, 1992;
Manning and Patierno, 1996). The ability of tumors to
exhibit autonomous growth has long been regarded as a
hallmark of a neoplasm. Whether in a primary tumor or a
metastasis, tumor cells must be able to survive in an
environment that is often toxic or severely depleted of
essential nutrients or growth factors (Nowell, 1976;
Farber and Cameron, 1980). Resistance to cytotoxicity
and a reduced requirement for exogenous growth factors
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have been shown to be associated with an increase in the
expression of genes that promote the acquisition of a
growth-factor-independent phenotype as well as resis-
tance to apoptosis. Several lines of evidence have impli-
cated Bcl-2 and several of its survival homologues in the
conversion of normal cells to malignancy (Collins, 1991;
Williams, 1991; Oren, 1992; Manning and Patierno, 1996).
As described earlier, the Bcl-2 gene was first identified at
the site of a translocation between chromosome 14 and
18 in a human non-Hodgkin's B-cell lymphoma. Unlike
most other oncogenes which promote cell cycle progres-
sion, overexpression of the Bcl-2 oncogene was found to
protect cells from undergoing apoptosis in response to a
number of stimuli (Miyashita and Reed, 1992, 1993). The
ability to confer the malignant phenotype in cells has
been demonstrated following the introduction of Bcl-2
into several immortalized cell types (Reed, 1994;
Korsmeyer, 1995). Also, the overexpression of the death
agonist Bax or related genes in cancer cells is able to
counteract the survival effect of Bcl-2 and induce apop-
tosis by elimiriating the effects of survival proteins (Han
et al., 1996; Sabbatini et al., 1997). Transgenic mice over-
expressing Bcl-2 develop polyclonal expansion of B-cells
that eventually progress to high-grade lymphomas
(McDonnell and Korsmeyer, 1991). Thus, Bcl-2 appears to
function as a checkpoint against unwarranted cell
turnover by preventing cells from undergoing apoptosis
(McDonnell et al., 1989). In addition to cells of the B-cell
lineage and other hematopoietic stem cells, Bcl-2 pro-
tein expression has been observed in several epithelial
stem cells but not in more differentiated cells, suggest-
ing that Bcl-2 may also have a protective function in stem
cells (Hockenbery et al., 1991). Bcl-x has also been
encountered to a limited extent in both normal and dis-
eased skin keratinocytes, but it is more highly and wide-
ly expressed in malignant keratinocytes of the skin
(Krajewski et al., 1994a; Wrone-Smith et al., 1995; Mitra et
al., 1997; Pena et al., 1997) and oral mucosa (Polverini,
Nickoloff, and Betz, unpublished observations).
In human cancers, overexpression of Bcl-2 protein
has been observed in several tumor types, including can-
cer of the lung (Pezzella et al., 1993), ovary (Henriksen et
al., 1995), colon (Sinicrope et al., 1995a,b), prostate
(Colombel et al., 1993), esophagus (Sarbia et al., 1996), and
breast.(Silvestrini et al., 1994). In non-small-cell lung can-
cer and breast cancer, Bcl-2 protein expression in tumor
cells correlates with a poorer prognosis as compared with
Bcl-2-negative tumors. Increased expression of Bcl-2 has
also been observed in precancerous lesions, and both
Bcl-2 and Bcl-xL/S have been detected in early dysplastic
lesions of the oral mucosa in humans and in carcinogen-
induced papillomas in a mouse model of multistep
tumorigenesis (Birchall et al., 1996; Jordan et al., 1996;
Stern et al., 1997). Overexpression of Bcl-2 is also associ-
ated with resistance of several human tumors to apopto-
sis-inducing chemotherapeutic agents such as
methotrexate, 1-,B-D-arabvinofuranosyl-cytosine, vin-
cristin, etoposide, and cisplatin (Barry et al., 1990).
Increased Bcl-2 expression has been observed in the pro-
gression of prostate cancer from androgen-dependent to
androgen-independent growth. McDonnell et al. (1992)
have reported that the majority of androgen-dependent
tumors exhibit low or barely detectable levels of Bcl-2,
while androgen-independent tumors express high levels
of this gene. Thus, it was hypothesized that Bcl-2 protects
tumors from apoptosis upon withdrawal of androgens.
As mentioned previously, Bax, another member of
the Bcl-2 family, functions to antagonize the survival
effect of Bcl-2. Mice with a targeted disruption in Bax dis-
play hyperplasia of thymocytes and B-cells. Recently, it
has been reported that loss of Bax expression may be a
prognostic indicator of diminished responsiveness to
chemotherapy and shorter survival in women with
metastatic breast cancer (Krajewski et at., 1995). Thus,
loss of a key inducer of apoptosis can also contribute to
tumor cell survival and progression. Lack of responsive-
ness to negative growth controls by tumor cells is anoth-
er mechanism whereby tumors are able to circumvent
apoptosis. It has been shown that resistance to trans-
forming growth factor-V-induced growth arrest and apop-
tosis correlates with tumor progression (Bursch et al.,
1993; Selvakumaran et al., 1994). Thus, these data strong-
ly implicate several members of the Bcl-2 gene family in
tumor progression by increasing the resistance of mutat-
ed cells against the protective mechanisms of apoptosis.
This can be achieved either by overexpression of Bcl-2
homologues that promote cell survival or downregula-
tion of genes that induce cell death.
Relation of Bcl-2 with Cellular Resistance to
Apoptosis and Malignant Transformation
Given the inherent role that apoptosis plays in the order-
ly removal of cells during development and in adult tis-
sues, apoptosis most likely functions to guard against
neoplastic development by eliminating genotoxically
damaged cells that accumulate in organs and tissues
(Manning and Patierno, 1996). This notion is supported
by the fact that the majority of cells exposed to carcino-
gens and chemotherapeutic agents undergo apoptosis.
In keeping with the concept that initiation by a carcino-
gen is a rare event, the process of apoptosis is generally
an efficient mechanism for removing genotoxically dam-
aged cells that escape the DNA repair process. This pos-
sibility is further supported by in vivo studies of liver and
skin carcinogenesis. Hepatocellular carcinoma can be
readily induced in rats following exposure to an initiating
dose of a chemical carcinogen along with a hepatotoxic
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agent such as carbon tetrachloride (Farber and Cameron,
1980). In this instance, liver damage is followed by com-
pensatory proliferation of residual hepatocytes. If, on the
other hand, the same carcinogen is administered at a
similar dose along with lead nitrate, an agent which
potently induces cell proliferation as well as apoptosis,
cancer development is prevented (Ledda-Columbano
and Columbano, 1991). However, when the removal of
damaged cells by apoptosis is compromised, or is less
efficient, the potential for tumor development increases.
This appears to be the case in the large intestine. This
organ tends to be the focus of carcinoma development
more frequently than the small intestine. This is despite
the fact that the small intestine exhibits a higher rate of
turnover. In keeping with the concept that apoptosis pro-
tects against carcinogenesis by destroying genotoxically
damaged cells, the failure to undergo apoptosis may
partly explain the protective effects conferred on car-
cinogen-initiated cells by tumor promoters.
The tumor-promoting agent phorbol ester 12-0-
tetradecanoylphorbol-13-acetate (TPA) has been shown
to inhibit apoptosis in cultures of C3H-lOTl/2 cells fol-
lowing exposure to ionizing radiation, low-energy ,B-radi-
ation, or acute serum deprivation (Tomei et al., 1988).
Also, treatment of chronic leukemia cells with TPA
markedly inhibits apoptosis induced by agents such as
cholchacine, etoposide, or methylprednisolone (Forbes
et al., 1992). The protective action of TPA is likely mediat-
ed through modulation of protein kinase C, since its
activity can be antagonized by inhibitors of this enzyme.
Okadaic acid, a tumor promoter that inhibits protein
phosphatases 1 and 2A, has been reported to protect
human lymphoid cells from induction of apoptosis by
diverse agents (Song et al., 1992). Exposure of liver cells
to okadaic acid inhibits apoptosis-associated dephos-
phorylation of several proteins, including a 40-kDa pro-
tein that is common in this tissue (Baxter and Lavin,
1992). These observations suggest that alteration in the
phosphorylation state of multiple specific proteins might
be an important regulatory mechanism involved not only
in cell proliferation but also in apoptosis. In vivo studies
also support the notion that suppression of apoptosis is
a feature of tumor promotion. In the rat hepatocyte
model of carcinogenesis, the formation of neoplastic foci
can be significantly enhanced if animals are treated with
an initiating dose of a carcinogen along with a tumor
promoter such as phenobarbital (Garcea et al., 1989;
Schulte-Hermann et al., 1990; Bursch et al., 1993). In this
model, phenobarbital increases the rate of tumor forma-
tion and the number of neoplastic foci. This effect is
associated with a decrease in the level of apoptosis with-
in the liver foci, since continuous exposure to phenobar-
bital does not produce a persistent increase in cell pro-
liferation. Interestingly, cessation of phenobarbital
administration results in a decrease in the number of
neoplastic foci due to induction of apoptosis. Thus, sev-
eral in vitro and in vivo studies suggest that tumor pro-
moters may enhance carcinogenesis by protecting muta-
genized cells from apoptotic death and allowing them to
proliferate and progress to preneoplasia and frank malig-
nancy. However, other studies (Stern et al., 1997) suggest
that this may not be the case.
In a recent study from the Conti laboratory (Stern et
al., 1997), the relationship between apoptosis and tumor
progression was examined in mouse skin tumors by
means of a two-stage chemical carcinogenesis protocol.
Papillomas were generated by exposing the skin of mice
to 7,12 dimethylbenzlalanthracine. The association
between tumor progression and apoptosis was analyzed
in tumors derived from two strains of mice differing in
their susceptibility to tumor development: the SINN and
SENCAR B/Pt mice. The TUNEL (terminal deoxynu-
cleotidyl transferase-mediated dUTP-biotin nick end
labeling) assay was used to identify apoptotic cells at
various times during tumor promotion. These workers
found that the number of apoptotic cells was greater in
papillomas that were in the process of undergoing pro-
gression to squamous cell carcinoma when compared
with benign papillomas. In addition, they found that
papillomas from SENCAR P/Bt mice, a tumor-progres-
sion-susceptible strain, had more apoptotic cells and
exhibited a substantial increase in p53 expression than
papillomas from tumor-progression-resistant SSIN mice.
These works suggested that, in this model system of skin
cancer, the epithelial cells populating tumors still main-
tained the capacity to undergo apoptosis and that the
presence of apoptotic cells in advanced papillomas was
an indicator of heightened endogenous mutagenic activ-
ity and high genomic instability.
Bcl-2 Synergizes with Oncogenes and
Tumor Suppressor Genes to Drive Cells
Toward Malignancy
Bcl-2 appears to cooperate in a synergistic fashion with
oncogenes and tumor suppressor genes to enhance the
survival of and the opportunity for additional mutations
to occur in cells. The translocation of the Bcl-2 gene in
human follicular B-cell lymphoma, although not suffi-
cient to cause malignant conversion of B-lymphocytes,
appears to increase the chance of additional mutations
in these abnormally long-lived cells. Studies of Bcl-2
transgenic mice provide support for the observation that
activation of an oncogene in cells overexpressing Bcl-2
increases the chances for a second mutational event to
occur (McDonnell et al., 1989; McDonnell and Korsmeyer,
1991). The indolent lymphoma that initially develops in
these mice after a long latency period progresses to a
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high-grade lymphoma. Many of these high-grade lym-
phomas were found to contain a constitutively activated
c-myc oncogene. This apparent synergistic effect was
confirmed in studies in which strains of mice overex-
pressing c-myc and Bcl-2 were crossed with each other.
The result of these matings was the rapid development
of a disseminated lymphoma in the double-expressing
mice (Strasser et al., 1990). The c-myc oncogene is a
potent stimulator of cell proliferation but also induces
apoptosis when overexpressed in the absence of sup-
porting growth factors. In this case, overexpression of
Bc1-2 appears to prevent cell death induced by c-myc, by
driving cells toward proliferation and by blocking apop-
tosis (Vaux et al., 1988). In nonlymphoid mesenchymal
cells such as primary rat embryo fibroblasts, Bcl-2
appears to cooperate with the Ha-ras oncogene to pro-
duce neoplastic transformation, and does so without
directly increasing cell proliferation (Reed et al., 1990).
Ras-mediated signal transduction pathways become
activated upon stimulation, and are subsequently inacti-
vated to maintain homeostasis. Mutated ras protein,
however, has lost the ability to become inactivated,
resulting in enhanced cell proliferation. Although the ras
signaling pathways have not yet been completely
defined, there is evidence that they may be linked to the
cell death pathway. The ras oncogenes have been shown
to increase resistance of NIH 3T3 cells to gamma-radia-
tion-induced apoptosis (Sklar, 1988). Bcl-2 interacts with
ras-related protein R-ras p23. Although the structure of
R-ras is similar to other ras proteins, its biological func-
tion differs, since R-ras does not share the oncogenic
properties of other members of this family of proteins.
The potential of ras involvement in the apoptotic path-
way is suggested by interaction of ras with Raf-1 kinase
(Fernandez-Sarabia and Bischoff, 1993). Bcl-2 together
with Raf-l synergistically suppress apoptosis induced by
growth factor withdrawal in 32D.3 hematopoietic cells
(Wang et al., 1994).
Inactivation of the p53 tumor suppressor gene has
been linked to the etiology of more than 50% of human
cancers and is one of the most frequently mutated genes
in tumors of the upper aerodigestive tract, including the
oral cavity (Hollstein et al., 1991; Levine et al., 1991; Field
et al., 1992). Recent studies have provided compelling
evidence that alteration in p53 expression may play an
important role in selecting for cells resistant to apopto-
sis during tumor development. Wild-type (WT) p53 regu-
lates the expression of cell cycle genes in normal cells at
the G1/S boundary. It functions as a guardian, maintain-
ing the fidelity of genomic information (Hollstein et al.,
1991; Levine et al., 1991). Thus, when transduced into
tumor cells, WT p53 effectively blocks cell cycle progres-
sion. WTp53 also appears to regulate Bcl-2 expression.
When introduced into growth-factor-independent tumor
cells, these cells become sensitive to growth factor with-
drawal and undergo apoptosis. However, the restoration
of WT p53 did not cause growth arrest, but rather cells in
the Gl phase of the cell cycle displayed enhanced sus-
ceptibility to apoptosis (Yonish-Rouach et at., 1991).
Expression of WTp53 in the EB tumor line, which lacks
endogenous p53 expression, induced apoptosis and pre-
vented tumor growth in vivo (Shaw et al., 1992).
Inactivation of p53 may therefore be a mechanism by
which tumor cells escape negative growth controls that
could lead to apoptosis. Mutated p53 genes that encode
proteins that act as negative dominant inhibitors of p53
can also inhibit apoptosis (Gottlieb et al., 1994; Zhu et al.,
1994). Expression of mutant p53 genes in IL-3-depen-
dent leukemia cells was found to protect cells from apop-
tosis following growth factor withdrawal (Zhu et al., 1994).
A mechanistic link between apoptosis and the func-
tion of the p53 tumor suppressor has recently been
described. Prior to the induction of apoptosis, WTp53
rapidly translocates into the nucleus, where it can func-
tion as a transcription factor regulating gene expression
(Levine et al., 1991). Two proteins regulated by p53 are
Bcl-2 and Bax (Miyashita et at., 1994; Miyashita and Reed,
1991). Expression of WT p53 in MI leukemia cells which
lack endogenous p53 resulted in down-regulation of Bcl-
2 together with up-regulation of Bax expression prior to
the occurrence of apoptosis (Miyashita et al., 1994;
Selvakumaran et al., 1994). Mice deficient in p53 have
been found to have elevated levels of Bcl-2 protein and
reduced levels of Bax in several tissues (Myashita et al.,
1994). In human cells exposed to ionizing radiation,
induction of Bax was associated with normal p53 func-
tion and apoptosis (Zhan et at., 1994). These data suggest
that p53 may regulate apoptosis by altering the cellular
ratio of Bcl-2/Bax and that it is this perturbation that
determines the fate of cells exposed to apoptotic stimuli.
In a recent publication from the Vogelstein group (Polyak
et al., 1997), it was reported that among 7000 transcripts
examined in p53-expressing cells, only 0.19% were found
to be markedly increased. Many of these genes were pre-
dicted to encode proteins that could generate or respond
to oxidative stress. It was concluded that p53 results in
apoptosis through a three-step process: (1) the tran-
scriptional induction of redox-related genes; (2) the for-
mation of reactive oxygen species; and (3) the oxidative
degradation of mitochondrial components, culminating
in cell death. In addition to preventing the generation of
reactive oxygen species and protecting mitochondrial
components from degradation, loss or inactivation of
p53 may also predispose preneoplastic cells to accumu-
late additional mutations through blocking of the normal
apoptotic response to genotoxic damage. Normal p53
has been demonstrated to be critical to the induction of
apoptosis in human and murine cells following genotox-
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ic damage (Lowe et al., 1993; Clarke et al., 1994; Fujiwara
et al., 1994; McCarthy et al., 1994; Merritt et al., 1994). Thus,
a p53 deficiency may permit a population of genetically
damaged cells to escape the normal process of apoptot-
ic deletion. Recently, Livingstone and colleagues (1992)
have suggested that loss of p53 function may predispose
cells to further genomic instability and lead to gene
amplification. These investigators found that gene
amplification occurred at a higher rate in p53-deficient
cells, whereas normal fibroblasts with one copy of the
normal p53 allele did not demonstrate similar gene
amplification.
Activation of Bcl-2 through inactivation or loss of
p53 might also enhance the growth of metastatic tumor
cells. Metastatic foci often translate to an environment
with limited nutrients. In normal cells, nutrient depriva-
tion is a potent stimulus for apoptosis. However, tumor
cells that have a decreased dependency on exogenous
growth factor or that overexpress survival genes such as
Bcl-2 would no longer be subjected to the selection pres-
sure normally associated with nutrient or growth factor
deprivation. Indeed, the expression levels of Bcl-2 and
Bcl-xL (a Bcl-2 homologue) are often markedly elevated
in invading and metastatic oral squamous carcinomas
(lordan et al., 1996; Polverini, Nickoloff, and Betz, unpub-
lished observations). Many oncogenic viral proteins
(such as the simian virus 40 large T-antigen, adenovirus
type 5 EIB, and human papillomavirus 16/18 E6) can
effectively disrupt the function of p53 by post-transla-
tional modification of WTp53 protein (Mormand et al.,
1992, Perry et al., 1993). The oncogenic potential of these
agents thus appears to work through the p53/Bcl-2 axis,
enhancing the survival of infected cells and perhaps pre-
disposing them to additional mutations.
Summary and Conclusions
The earliest step in the carcinogenic process involves the
emergence of "initiated" cell populations that are genet-
ically altered. These are biologically indolent cells that
do not express any of the conventional markers of pre-
malignancy or malignancy but nevertheless have
acquired a selective growth advantage that renders them
at risk for further genetic damage. The enhanced expres-
sion of Bcl-2 and/or Bcl-xL in human premalignant and
malignant oral keratinocytes suggests that perhaps an
early key event in the development of oral squamous car-
cinoma is the preferential expression of members of the
Bcl-2 gene family that protect cells from apoptosis and
render them more susceptible to mutation and tumor
progression. In normal circumstances, the process of
apoptosis effectively eliminates genetically damaged
cells from tissues to guard against their continued
growth and progression toward malignancy. If, on the
other hand, these controls are compromised, then an
important mechanism for the removal of damaged cells
is lost. Surviving cells that contain sublethal DNA dam-
age would continue to persist in a protected environ-
ment and eventually may become hyperresponsive to
proliferative signals. Since drug resistance appears to be
a feature of cells overexpressing survival genes, this
would provide another explanation for the resistance to
cytotoxicity that characterizes initiated cell populations.
The continued persistence of apoptosis-resistant cells
would further increase the probability of acquiring addi-
tional mutations. Thus, for neoplastic growth to occur,
the selection pressure conferred on cells by the apoptot-
ic program must be overcome. This would in turn create
an imbalance between those forces that drive cells
toward proliferation and physiological independence
and those that keep cells tightly in check through apop-
tosis. Once this imbalance in favor of cell proliferation
and/or survival is achieved, cell growth would predomi-
nate. Genetic mutations or epigenetic factors that dimin-
ish the tendency to undergo apoptosis may then facili-
tate their growth and drive them toward malignancy.
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